Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.
|Articles|March 24, 2020
PsychPearls: Battling Anxiety During the COVID-19 Pandemic
Author(s)Joshua C. Morganstein, MD
How can psychiatrists advise patients to manage their stress and to remain calm?
Advertisement
Dr Joshua Morganstein, Chair of the American Psychiatric Association Committee on the Psychiatric Dimensions of Disaster, answers this question: There is a lot of panic, and anxiety/stress is on the rise, even in people without mental illness. How can psychiatrists advise patients to manage this stress and to remain calm?
Have more COVID concerns and clinical tips? Email us at
Advertisement
Related to this article
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
2
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
3
Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder
4
New Analyses of HLP003 for the Adjunctive Treatment of MDD
5